Biosensor-controlled gene therapy/drug delivery with nanoparticles for nanomedicine

Prow, T. W., Rose, W. A., Wang, N., Reece, L. M., Lvov, Y. and Leary, J. F. (2005). Biosensor-controlled gene therapy/drug delivery with nanoparticles for nanomedicine. In: Tuan Vo-Dinh, Warren S. Grundfest, David A. Benaron and Gerald E. Cohn, Advanced Biomedical and Clinical Diagnostic Systems III. Conference on Advanced Biomedical and Clinical Diagnostic Systems III, San Jose, CA, U.S.A., (199-208). 23-25 January 2005. doi:10.1117/12.589422

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ237942_OA.pdf Full text (open access) application/pdf 725.21KB 0

Author Prow, T. W.
Rose, W. A.
Wang, N.
Reece, L. M.
Lvov, Y.
Leary, J. F.
Title of paper Biosensor-controlled gene therapy/drug delivery with nanoparticles for nanomedicine
Conference name Conference on Advanced Biomedical and Clinical Diagnostic Systems III
Conference location San Jose, CA, U.S.A.
Conference dates 23-25 January 2005
Proceedings title Advanced Biomedical and Clinical Diagnostic Systems III   Check publisher's open access policy
Journal name Proceedings of SPIE   Check publisher's open access policy
Place of Publication Bellingham, WA, U.S.A.
Publisher SPIE - International Society for Optical Engineering
Publication Year 2005
Sub-type Fully published paper
DOI 10.1117/12.589422
Open Access Status File (Publisher version)
ISBN 9780819456663
ISSN 1996-756X
Editor Tuan Vo-Dinh
Warren S. Grundfest
David A. Benaron
Gerald E. Cohn
Volume 5692
Start page 199
End page 208
Total pages 10
Language eng
Formatted Abstract/Summary
Nanomedicine involves cell-by-cell regenerative medicine, either repairing cells one at a time or triggering apoptotic pathways in cells that are not repairable. Multilayered nanoparticle systems are being constructed for the targeted delivery of gene therapy to single cells. Cleavable shells containing targeting, biosensing, and gene therapeutic molecules are being constructed to direct nanoparticles to desired intracellular targets. Therapeutic gene sequences are controlled by biosensor-activated control switches to provide the proper amount of gene therapy on a single cell basis. The central idea is to set up gene therapy "nanofactories" inside single living cells. Molecular biosensors linked to these genes control their expression. Gene delivery is started in response to a biosensor detected problem; gene delivery is halted when the cell response indicates that more gene therapy is not needed.

Cell targeting of nanoparticles, both nanocrystals and nanocapsules, has been tested by a combination of fluorescent tracking dyes, fluorescence microscopy and flow cytometry. Intracellular targeting has been tested by confocal microscopy. Successful gene delivery has been visualized by use of GFP reporter sequences. DNA tethering techniques were used to increase the level of expression of these genes. Integrated nanomedical systems are being designed, constructed, and tested in-vitro, ex-vivo, and in small animals.

While still in its infancy, nanomedicine represents a paradigm shift in thinking – from destruction of injured cells by surgery, radiation, chemotherapy to cell-by-cell repair within an organ and destruction of non-repairable cells by natural apoptosis.
Subjects 100709 Nanomedicine
Q-Index Code E1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes Published under "Nanomedicine and Advanced Techniques".

Document type: Conference Paper
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 22 Mar 2011, 10:56:14 EST by Dr Tarl Prow on behalf of Medicine - Princess Alexandra Hospital